Acute kidney injury in critically ill cirrhotic patients: A review

Annals of Hepatology

Volumn 11, Issue 3, 2012, Pages 301-310

  Muciño Bermejo, Jimena ^a   Carrillo Esper, Raúl ^a   Uribe, Misael ^a   Méndez Sánchez, Nahum ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

Hepatorenal syndrome; Intensive care unit; Renal failure

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; MESSENGER RNA; MIDODRINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NORADRENALIN; OCTREOTIDE; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; ASCITES; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DELAYED DIAGNOSIS; DOPPLER ECHOGRAPHY; HEMODIALYSIS; HEPATORENAL SYNDROME; HUMAN; HYPONATREMIA; INTENSIVE CARE UNIT; KIDNEY FUNCTION TEST; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PREVALENCE; PROGNOSIS; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

EID: 84859316741     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30924-x     Document Type: Review

References (62)

1. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448-60.
2. Singri N, Ahya SN, Levin ML. Acute renal failure. JAMA 2003; 289: 747-51.
3. Ng CKF, Chan MHM, Tai MHL, Lam CWK. Hepatorenal syndrome. Clin Biochem Rev 2007; 28: 11-7.
4. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes, Angeli P, et al. Working Party proposal for a revised clas sification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-9.
5. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol 2007; 13: 5552-9.
6. Slack AJ, Wendon J. The liver and kidney in critically ill patients. Blood Purif 2009; 28: 124-34.
7. Anon. Hepatorenal syndrome or hepatic nephropathy? Lancet 1980; 315: 801-2.
8. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
9. Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G, Shaw S, et al. Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther 2006; 1: 883-93.
10. García-Tsao G, Parikh C, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-77.
11. Warner NS, Cuthbert JA, Bhore R, Rockey DC. Acute kidney injury and chronic kidney disease in hospitalized patients with cirrhosis. J Investig Med 2011; 59:1244-51.
12. Montoliu S, Ballesté B, Planas R, Álvarez MA, Rivera M, Miquel M, Masnou H, et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol 2010; 8: 616-22.
13. Tinti F, Umbro I, Giannelli V, Merli M, Ginanni Corradini S, Nofroni I, et al. Acute renal failure in liver transplant recipients: role of pretransplantation renal function and 1-year follow-up. Transplant Proc 2011; 43: 1136-8.
14. Biagioni E, Cavazzuti I, Busani S, Trevisan D, Zavatti L, Ferrari E, Massimo G, et al. Acute renal failure and renal replacement therapy in the postoperative period of orthotopic liver transplant patients versus non elective abdominal surgery patients. Transplant Proc 2011; 43: 1145-7.
15. Cholongitas E, Calvaruso V, Senzolo M, Patch D, Shaw S, O'Beirne J, Burroughs AK. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol 2009; 24: 1639-47.
16. Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, Pavesi M, et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol 2012; 13 [In press].
17. Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA, Moon YS. Renal dysfunction induced by bacterial infection other than spontaneous bacterial peritonitis in patients with cirrhosis: incidence and risk factors. Gut Liver 2009; 3: 292-7.
18. Perdomo Coral G, Alves de Mattos A. Renal impairment after spontaneous bacterial peritonitis: incidence and prognosis. Can J Gastroenterol 2003; 17: 187-90.
19. Jung ES, Lee JS, Kim MH, Kim NH, Kim KA, Moon YS. Renal dysfunction after spontaneous bacterial peritonitis in cirrhosis: incidence and risk factors. Korean J Gastroenterol 2006; 48: 401-7.
20. Goykhman Y, Ben-Haim M, Rosen G, Carmiel-Haggai M, Oren R, Nakache R, Szold O, et al. Transjugular intrahepatic portosystemic shunt: current indications, patient selection and results. Isr Med Assoc J 2010; 12: 687-91.
21. Gaba RC, Omene BO, Podczerwinski ES, Knuttinen MG, Cotler SJ, Kallwitz ER, Berkes JL, et al. TIPS for treatment of variceal hemorrhage: clinical outcomes in 128 patients at a single institution over a 12-year period. J Vasc Interv Radiol 2012; 23: 227-35.
22. Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68: 362-70.
23. Bittencourt PL, de Carvalho GC, de Andrade Regis C, Kalil JR, Cerqueira LA, Barbosa DS, da Silva Nery M, et al. Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality. Ann Hepatol 2012; 11: 90-5.
24. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37: 233-43.
25. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-90.
26. Olteanu D, Lupu D. The kidney in cirrhosis with portal hypertension. J Med Life 2010; 3: 175-7.
27. Ginès P, Wong R, Milutinovic S, Ruiz L, Olteanu D. Effects of Satavaptan (SR 121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia. J Hepatol 2006; 44; 204-13.
28. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41: 422-33.
29. Salerno F, Badalamenti S. Drug induced renal failure in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier W (eds.). Ascites and Renal Dysfunction in Liver Disease. 2nd. ed. Malden, MA: Blackwell; 2005, p. 372-82.
30. Cardenas A, Ginès P. Hepatorenal Syndrome: Current Concepts. In: De Franchis R (ed.). Portal hypertension IV. Proceedings of the 4th International Consensus Workshop on Methodology and Treatment. Blackwell; 2004.
31. Huisman EJ, Trip EJ, Siersema PD, van Hoek B, van Erpecum KJ. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011; 23: 982-9.
32. Guglielmi FW, Panella C, Buda A, Budillon G, Caregaro L, Clerici C, Conte D, et al. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism. Multicentre prospective study by the 'Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2005; 37: 681-8.
33. Badiou S, Dupuy AM, Descomps B, Cristolead JP. Comparison between the enzymatic vitro assay for creatinine determination and three other methods adapted on the Olympus analyzer. J Clin Lab Anal 2003; 17: 235-40.
34. Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D, Thomas M, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transplant 2007; 13: 523-9.
35. Cholongitas E, Shusang V, Marelli L, Nair D, Thomas M, Patch D, Burns A, et al. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-78.
36. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605-13.
37. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 2005; 579: 773-7.
38. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, et al. Identification of neutrophil gelatinase-as sociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-43.
39. Gerbes AL, Benesic A, Vogeser M, Krag A, Bendtsen F, Møller S. Serum neutrophil gelatinase-associated lipocalin-a sensitive novel marker of renal impairment in liver cirrhosis? Digestion 2011; 84: 82-3.
40. Madan K, Mehta A. Management of renal failure and ascites in patients with cirrhosis. Int J Hepatol 2011; 79: 2-7.
41. Alves de Mattos A. Current indications for the use of albumin in the treatment of cirrhosis. Ann Hepatol 2011: 10: S15-S20.
42. Arroyo V, Fernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011; 10: S6-S14.
43. Proulx NL, Akbari A, Garg AX, Rostom A, Jaffey J, Clark HD. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005; 20: 1617-22.
44. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, et al. Noradrenalin vs. terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatology 2007; 47: 499-505.
45. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
46. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009; 43: 680-5.
47. Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007; 52: 742-8.
48. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 2011; 58: 928-38.
49. Wong LP, Blackley MP, Andreoni KA, Chin H, Falk RJ, Klemmer PJ. Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy. Kidney Int 2005; 68: 362-70.
50. Davenport A, Bouman C, Kirpalani A, Skippen P, Tolwani A, Mehta RL, Palevsky PM. Delivery of renal replacement therapy in acute kidney injury: what are the key issues? Clin J Am Soc Nephrol 2008; 3: 869-75.
51. Davenport A. Renal replacement therapy in the patient with acute brain injury. Am J Kidney Dis 2001; 37: 457-66.
52. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 1993; 21: 328-38.
53. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 1993; 41: S245-S251.
54. Gonwa TA, Wadei HM. The challenges of providing renal replacement therapy in decompensated liver cirrhosis. Blood Purif 2012; 20: 144-8.
55. Aggarwal A, Mitchell JE, Hanouneh I, Atreja A, Zein N. The effect of transjugular intrahepatic portosystemic shunt on renal function in patients with liver cirrhosis. Gastroenterology 2011; 140: S958.
56. Anderson CL, Saad WE, Kalagher SD, Caldwell S, Sabri S, Turba UC, Matsumoto AH, et al. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience. J Vasc Interv Radiol 2010; 21: 1370-6.
57. Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O, Navasa M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatology 2004; 40: 140-6.
58. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, Duhamel C, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-82.
59. Fede G, D'Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, Morabito A, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2011; 10: 1-9.
60. Wadei HM, Gonwa TA. Hepatorenal syndrome in the intensive care unit. J Intensive Care Med 2011; 2: 1-3.
61. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-96.
62. Das V, Boelle PY, Galbois A, Guidet B, Maury E, Carbonell N, Moreau R, et al. Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med 2010; 38: 2108-16.